MAYZENT
As listed in the register: MAYZENT
2 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Siponimod
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (MAYZENT). It describes the substance, not this exact product.
Siponimod is an S1P receptor modulator.
Siponimod binds with high affinity to S1P receptors 1 and 5.
Siponimod is extensively metabolized, mainly via CYP2C9 accounting for 80% of the metabolism in those who are normal metabolizers (i.e., those with the CYP2C9*1/*1 genotype).
Siponimod absorption is extensive (greater than or equal to 70%, based on the amount of radioactivity excreted in urine and the amount of metabolites in feces extrapolated to infinity).
Food Effect Food intake resulted in delayed absorption (the median T max increased by approximately 2 to 3 hours).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-30
Safety of the active substance
From the US prescribing label for the same active substance (MAYZENT). It describes the substance, not this exact product.
- Observed reactions include angioedema [see Warnings and Precautions (5.8)].
- Patients with a CYP2C9*3/*3 genotype.
- ( 4 ) In the last 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
- ( 4 ) Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker.
The most common adverse reactions (incidence at least 10%) in MAYZENT-treated patients in Study 1 were headache, hypertension, and transaminase increases.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Siponimod |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 2 mg |
| Form | tablet |
| Classification | L04AE03 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02496437 |
| DPD drug code | 98631 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.